|
gptkbp:instanceOf
|
gptkb:drug
triptan
|
|
gptkbp:approvalYear
|
2001
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N02CC07
|
|
gptkbp:bioavailability
|
20-30%
|
|
gptkbp:brand
|
Frova
|
|
gptkbp:CASNumber
|
158747-02-5
|
|
gptkbp:category
|
serotonin receptor agonist
|
|
gptkbp:chemicalClass
|
indole derivative
|
|
gptkbp:contraindication
|
ischemic heart disease
uncontrolled hypertension
history of stroke
|
|
gptkbp:developer
|
gptkb:Vernalis
|
|
gptkbp:eliminationHalfLife
|
26 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:hasMolecularFormula
|
C14H17N3O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Frovatriptan
|
|
gptkbp:IUPACName
|
(R)-6-Cyano-1-methyl-5-(1-methylpiperidin-4-yl)-1,2,3,4-tetrahydrocarbazole
|
|
gptkbp:KEGGID
|
D04124
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
5-HT1B/1D receptor agonist
|
|
gptkbp:meltingPoint
|
207-209°C
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
15%
|
|
gptkbp:PubChem_CID
|
60723
54718
CHEMBL1201356
DB00952
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
fatigue
dry mouth
flushing
|
|
gptkbp:synonym
|
Frova
Frovatriptan succinate
|
|
gptkbp:UNII
|
K72T3FS567
|
|
gptkbp:usedFor
|
migraine
|
|
gptkbp:bfsParent
|
gptkb:Triptans
|
|
gptkbp:bfsLayer
|
7
|